Performance of Ir(III)-Based Anticancer Agents in the Treatment of Cisplatin-Resistant Cancer Cells,ChemMedChem

当前位置： X-MOL 学术 › ChemMedChem › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Performance of Ir(III)-Based Anticancer Agents in the Treatment of Cisplatin-Resistant Cancer Cells
ChemMedChem ( IF 3.6 ) Pub Date : 2022-06-20 , DOI: 10.1002/cmdc.202200273
Meng-Meng Wang ₁ , Hao-Ming Li ₁ , Dong-Ping Deng ₁ , Yan Su ₁ , Zhi Su ₁

Affiliation

A path toward re-sensitizing: Our work developed and demonstrated the effectiveness of a mitochondria-relevant strategy in the treatment of cisplatin-resistant cancer cells, which could pave the way for developing new metallodrugs to overcome cisplatin resistance.

中文翻译：